Humacyte Inc. (NASDAQ:HUMA) shares traded 8.26% higher at $2.49 on Wall Street last session.
In accordance with the data, 6 analysts cover Humacyte Inc. (NASDAQ:HUMA). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $2.75, we find $7.00. Given the previous closing price of $2.30, this indicates a potential upside of 204.35 percent. HUMA stock price is now -13.05% away from the 50-day moving average and -40.19% away from the 200-day moving average. The market capitalization of the company currently stands at $248.78M.
It has been rated a hold by 0 analysts and a buy by 5. Brokers who have rated the stock have averaged $9.63 as their price target over the next twelve months.
With the price target reduced from $10 to $4, Piper Sandler Downgraded its rating from Overweight to Underweight for Humacyte Inc. (NASDAQ: HUMA). On October 29, 2021, Cowen recently initiated its ‘Outperform’ rating on the stock quoting a target price of $17, while ‘Oppenheimer’ rates the stock as ‘Outperform’.
In other news, Sander Dale A., CFO and Chief Corp. Deve. Off. bought 20,000 shares of the company’s stock on Dec 16. The stock was bought for $52,000 at an average price of $2.60. Upon completion of the transaction, the CFO and Chief Corp. Deve. Off. now directly owns 20,600 shares in the company, valued at $51294.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 16, President, CEO and Director Niklason Laura E sold 239,538 shares of the business’s stock. A total of $606,031 was realized by selling the stock at an average price of $2.53. This leaves the insider owning 17,990,736 shares of the company worth $44.8 million. Insiders disposed of 1,399,460 shares of company stock worth roughly $3.48 million over the past 1 year. A total of 20.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HUMA stock. A new stake in Humacyte Inc. shares was purchased by HAMILTON LANE ADVISORS LLC during the first quarter worth $131,000. SIMPLEX TRADING, LLC invested $101,000 in shares of HUMA during the first quarter. In the first quarter, ERGOTELES LLC acquired a new stake in Humacyte Inc. valued at approximately $78,000. TEACHER RETIREMENT SYSTEM OF TEXAS acquired a new stake in HUMA for approximately $46,000. SG AMERICAS SECURITIES, LLC purchased a new stake in HUMA valued at around $27,000 in the second quarter. In total, there are 117 active investors with 12.30% ownership of the company’s stock.
Humacyte Inc. (NASDAQ: HUMA) opened at $2.3100 on Tuesday. During the past 12 months, Humacyte Inc. has had a low of $1.96 and a high of $8.04. As of last week, the company has a debt-to-equity ratio of 0.42, a current ratio of 9.80, and a quick ratio of 9.80. The fifty day moving average price for HUMA is $2.8638 and a two-hundred day moving average price translates $4.1635 for the stock.
The latest earnings results from Humacyte Inc. (NASDAQ: HUMA) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.25, missing analysts’ expectations of -$0.21 by -0.04. This compares to -$0.72 EPS in the same period last year. The company reported revenue of $31000.0 for the quarter, compared to $0.24 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -87.14 percent. For the current quarter, analysts expect HUMA to generate $200k in revenue.
Humacyte Inc.(HUMA) Company Profile
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.